(thirdQuint)Expanded Access for Pembrolizumab (MK-3475).

 Pembrolizumab has been approved by the U.

S.

 Food and Drug Administration for the treatment of patients with Glioblastoma and Melanoma The Expanded Access Program (EAP) for this medicine in the U.

S.

 is closed.

 The EAP will continue outside the U.

S.

.

 Expanded Access for Pembrolizumab (MK-3475)@highlight

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors.

 The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

